title: Effect of verapamil on the prognosis of patients with early postinfarction electrical or mechanical complications. The Danish Verapamil Infarction Trial II (DAVIT II).
abstract: The Danish Verapamil Infarction Trial II (DAVIT II) demonstrated from the second postinfarction week, that long term treatment with verapamil significantly improved reinfarction free survival after an acute myocardial infarction (AMI). The present post hoc analysis of DAVIT II was undertaken with the purpose of evaluating the effect of treatment with verapamil in patients with early electrical complications, i.e. ventricular or atrial fibrillation, ventricular tachycardia, or second or third degree atrioventricular block, with or without mechanical complication, i.e. heart failure, during the first post-AMI week. In the placebo group, the 18-month mortality rate was lowest (9.5%) in patients without electrical or mechanical complications, highest (24.6%) in patients with electrical events only, and in-between (17.5%) in patients with mechanical problems regardless of presence of electrical complications. Verapamil significantly reduced the 18-month mortality rate in patients with early electrical without mechanical complications (60% reduction, P = 0.02), and in patients without mechanical complications (35% reduction, P = 0.02). Verapamil did not change the mortality rate in patients with mechanical complications.
authors.affiliation: Department of Internal Medicine B, County Hospital of Hillerød, Denmark.
authors.forename: M
authors.initials: M
authors.lastname: Vaage-Nilsen
authors.forename: J F
authors.initials: JF
authors.lastname: Hansen
authors.forename: K
authors.initials: K
authors.lastname: Mellemgaard
authors.forename: L
authors.initials: L
authors.lastname: Hagerup
authors.forename: B
authors.initials: B
authors.lastname: Sigurd
authors.forename: E
authors.initials: E
authors.lastname: Steinmetz
mesh_terms: D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000401:mortality*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000209:etiology / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D011433:Propranolol / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D011433:Propranolol; D014700:Verapamil